# Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01052298** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 25 (actual)

## Conditions studied

- Disease, Pulmonary

## Interventions

- **DRUG:** Ciprofloxacin (Cipro inhale, BAYQ3939)
- **DRUG:** Ciprofloxacin (Cipro inhale, BAYQ3939)
- **DRUG:** Ciprofloxacin (Cipro inhale, BAYQ3939)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01052298
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01052298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01052298, "Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01052298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*